A RANDOMIZED, OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF CEMACABTAGENE ANSEGEDLEUCEL IN PARTICIPANTS WITH MINIMAL RESIDUAL DISEASE AFTER RESPONSE TO FIRST LINE THERAPY FOR LARGE B-CELL LYMPHOMA (ALPHA3)

The study aims to see if CAR T cells made from healthy donors are an effective study treatment to prevent relapse in participants who have lymphoma DNA detected in their blood by an investigational test. The study evaluates two investigational products – ALLO- 647, an antibody (protein) that may help prepare the body for receiving CAR T cells from healthy donors, and a CAR T cell study treatment called cemacabtagene ansegedleucel or cema-cel. Both ALLO-647 and cema-cel are investigational drugs and therefore not approved by the Food and Drug Administration (FDA). For reference, CAR T cells are T cells (a type of immune system white blood cell) that have been engineered to attack cancer cells, like lymphoma.

Are you Eligible? (Inclusion Criteria)

• Participant has a diagnosis of Large B-cell lymphoma confirmed by doctor - Participant must be 18 years of age or older at the time of signing the ICF - Participants cannot have a history of CNS lymphoma (primary or secondary)